The Company regularly evaluates its business and objectives to ensure that it is properly configured and sized based on changing market conditions. Accordingly, the Company has implemented certain restructuring initiatives, including consolidation of certain facilities throughout the world and rationalization of its operations. In the second quarter of fiscal year 2025, management initiated a restructuring plan to streamline operations of the Company's global genomics business.

The Company’s restructuring charges consist of severance payments, costs for outplacement services, and post-employment benefits (collectively, “employee separation costs”), other related exit costs and asset impairment charges related to restructuring activities. These amounts are partially recorded within cost of service revenues and partially recorded within general and administrative expense on the condensed consolidated statements of operations.

Restructuring charges by segment were as follows:


	Three months ended February 28/29,					Nine months ended February 28/29,
	2025			2024		2025		2024
Food Safety	$	305		$	131	$	1,941	$	347
Animal Safety		(137	)		199		6,940		1,528
Corporate		—			608		1,225		1,478
Total	$	168		$	938	$	10,106	$	3,353

Restructuring activity for the nine months ended February 28, 2025 was as follows:


	Employee Separation Costs			Other Exit Costs			Total
Balance as of May 31, 2024	$	-		$	-		$	-
Expense		2,420			7,686			10,106
Cash Payments		(1,727	)		(490	)		(2,217	)
Asset impairments and other		-			(7,196	)		(7,196	)
Balance as of February 28, 2025	$	693		$	-		$	693